Login / Signup

Biologicals in childhood severe asthma: the European PERMEABLE survey on the status quo.

Elisangela ValenteHeike Buntrock-DöpkeRola Abou TaamStefania ArasiArzu BakirtasJaime Lozano BlascoKlaus BønnelykkeMihai CraiuRenato CutreraAntoine DeschildreBasil ElnazirLouise J FlemingUrs FreyMonika GappaAntonio Nieto GarcíaKirsten Skamstrup HansenLaurence HanssensKarina Jahnz-RozykMilos JesenakSebastian KerzelMatthias V KoppGerard H KoppelmanUroš KrivecKenneth A MacLeodMika MäkeläErik MelénGyörgyi MezeiAlexander MöllerVanessa Garcia-LarsenPetr PohunekPredrag MinićNiels W P RutjesPatrick SammutNicolaus SchwerkZsolt SzépfalusiMirjana TurkaljIren TzotchevaAlexandru UlmeanuStijn VerhulstParaskevi XepapadakiJakob NiggelSusanne VijverbergAnke H Maitland-van der ZeeUroš PotočnikSusanne M ReinartzCornelis M van DrunenMichael Kabesch
Published in: ERJ open research (2021)
Substantial differences exist in the management of childhood severe asthma across Europe, and the need for further studies on biomarkers supporting selection of biologicals, on criteria to assess therapy response and on how/when to end therapy in stable patients is evident.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • cross sectional
  • stem cells
  • childhood cancer
  • mesenchymal stem cells
  • young adults
  • cell therapy
  • patient reported